Adolescents receive a weight-based dose equivalent to the 50 mg adult dose ; Adolescents 12-17 years old who complete participation in the pharmacokinetic (PK) run-in study will b ...

today announced positive twenty-four month results from its Open-Label Extension (OLE) Study of EPITOPE (Phase 3 trial of VIASKIN® peanut 250 µg [VP250] in toddlers ages 1 to 3 years). The data ...

(Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to discovering, developing, and delivering life-changing therapeutics for patients in need, today announced new compelling ...